FDA Awards $18 Million in Grants for Advancing Treatment of Rare Diseases
Key claim: The FDA awarded $2 million to OncImmune for CD24Fc to prevent graft-versus-host disease in MPN transplant patients and $750,000 to Johns Hopkins for CD8-reduced T cells targeting MDS/AML in MPN progression.
Abstract
FDA awarded grants through Orphan Products Clinical Trials Grants Program, including $2 million to Oncolmmune (CD24Fc for graft-versus-host disease prevention in MPN transplant patients) and $750,000 to Johns Hopkins (CD8-reduced T cells for MDS/AML in MPN progression).
Why this matters
Federal grant funding signals which therapeutic directions are being prioritized for the still-unsolved problems in MPN transplant: GVHD prevention (where JAK inhibitors dominate but tolerability and efficacy gaps remain) and post-MPN AML transformation (where bridging and post-transplant relapse drive most decision-layer harm). CD24Fc and CD8-reduced T cells don’t change current referral or timing decisions, but they preview a near-future where execution-layer options expand beyond JAK inhibitors and HMAs — potentially shifting which AP/BP and older/unfit patients are considered transplant-eligible.